. . "RIV/00216208:11130/11:7266!RIV12-MZ0-11130___" . "[25610A9B8B8C]" . "Pokorna, K." . "Poly I: C-activated dendritic cells that were generated in CellGro for use in cancer immunotherapy trials"@en . . . "http://www.translational-medicine.com/content/pdf/1479-5876-9-223.pdf" . . "000299108200001" . . "GB - Spojen\u00E9 kr\u00E1lovstv\u00ED Velk\u00E9 Brit\u00E1nie a Severn\u00EDho Irska" . "Ul\u010Dov\u00E1, Hana" . . . "223" . "7"^^ . "221187" . "11130" . "9" . . . . "Fu\u010D\u00EDkov\u00E1, Jitka" . . "Background: For clinical applications, dendritic cells (DCs) need to be generated using GMP-approved reagents. In this study, we tested the characteristics of DCs generated in two clinical grade culture media and activated by three maturation stimuli, Poly I: C, LPS and the mixture of proinflammatory cytokines in order to identify the optimal combination of culture media and activation stimulus for the clinical use. Method: We tested DCs generation using two GMP-certified culture media, CellGro and RPMI+5% human AB serum and evaluated DCs morphology, viability and capapability to mature. We tested three maturation stimuli, PolyI:C, LPS and the mixture of proinflammatory cytokines consisting of IL-1, IL-6, TNF and prostaglandin E2. We evaluated the capacity of activated DCs to induce antigen-specific T cells and regulatory T lymphocytes. Results: Cell culture in CellGro resulted in a higher yield of immature DCs resulting from increased number of adherent monocytes. DCs that were generated in CellGro and activated using Poly I:C were the most efficient in expanding antigen-specific T cells compared to the DCs that were generated in other media and activated using LPS or the cocktail of proinflammatory cytokines. A comparison of all tested combinations revealed that DCs that were generated in CellGro and activated using Poly I:C induced low numbers of regulatory T cells. Conclusion: In this study, we identified monocyte-derived DCs that were generated in CellGro and activated using Poly I:C as the most potent clinical-grade DCs for the induction of antigen-specific T cells."@en . "Poly I: C-activated dendritic cells that were generated in CellGro for use in cancer immunotherapy trials"@en . . . "1479-5876" . "Budinsk\u00FD, V\u00EDt" . "8"^^ . . "Journal of Translational Medicine" . "Background: For clinical applications, dendritic cells (DCs) need to be generated using GMP-approved reagents. In this study, we tested the characteristics of DCs generated in two clinical grade culture media and activated by three maturation stimuli, Poly I: C, LPS and the mixture of proinflammatory cytokines in order to identify the optimal combination of culture media and activation stimulus for the clinical use. Method: We tested DCs generation using two GMP-certified culture media, CellGro and RPMI+5% human AB serum and evaluated DCs morphology, viability and capapability to mature. We tested three maturation stimuli, PolyI:C, LPS and the mixture of proinflammatory cytokines consisting of IL-1, IL-6, TNF and prostaglandin E2. We evaluated the capacity of activated DCs to induce antigen-specific T cells and regulatory T lymphocytes. Results: Cell culture in CellGro resulted in a higher yield of immature DCs resulting from increased number of adherent monocytes. DCs that were generated in CellGro and activated using Poly I:C were the most efficient in expanding antigen-specific T cells compared to the DCs that were generated in other media and activated using LPS or the cocktail of proinflammatory cytokines. A comparison of all tested combinations revealed that DCs that were generated in CellGro and activated using Poly I:C induced low numbers of regulatory T cells. Conclusion: In this study, we identified monocyte-derived DCs that were generated in CellGro and activated using Poly I:C as the most potent clinical-grade DCs for the induction of antigen-specific T cells." . "10"^^ . "Poly I: C-activated dendritic cells that were generated in CellGro for use in cancer immunotherapy trials" . "P(NT11559)" . "Poly I: C-activated dendritic cells that were generated in CellGro for use in cancer immunotherapy trials" . . "Ro\u017Ekov\u00E1, Daniela" . . . "Sochorov\u00E1, Kl\u00E1ra" . "cancer immunotherapy; dendritic cells; Poly I:C; culture media; clinical use"@en . . . . "RIV/00216208:11130/11:7266" . . "Bart\u016F\u0148kov\u00E1, Ji\u0159ina" . "\u0160p\u00ED\u0161ek, Radek" . . .